iXCells Forms Collaboration To Evaluate Chemotherapy Toxicity
iXCells Biotechnologies on March 25, 2026 announced an international collaboration with Rosebud Biosciences, Kantify, and Incite to evaluate off‑target chemotherapeutic toxicities using patient‑specific organoids. The partners will reprogram a liposarcoma patient's PBMCs into hiPSCs, generate heart, liver, and kidney organoids, and apply Kantify's investigational compounds with longitudinal imaging and machine‑learning analyses to produce personalized multi‑organ toxicity profiles informing therapy decisions.
Scoring Rationale
Official cross‑company collaboration with experimental patient‑derived organoids drives translational relevance; limited novelty and narrow, pilot-scale scope.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
